Active Clients

Akeso Therapeutics

Developing a curative therapy for metastatic or refractory/recurrent hematological cancers utilizing T-cells that have been genetically modified via the Sleeping Beauty transposon system (a leading non-viral vector for gene therapy) to express synthetic chimeric antigen receptor (CAR). This has shown promising clinical efficacy in the treatment of acute lymphoblastic leukemia.

Founder: Xianzheng Zhou, Ph.D., M.D.


Nutrition21 is an industry-leading developer and marketer of efficacious, high-value, clinically substantiated ingredients for use in dietary supplements, functional foods and beverages. With decades of experience, the company’s scientific platform has continued to create unique, patented products that are both safe and clinically effective. To build consumer trust, Nutrition21 ensures product efficacy and safety through a product development process that involves rigorous preclinical and clinical research. The company currently holds over 100 domestic and international issued and pending patents for its ingredients which support unique claims associated with sports nutrition, weight management, cognitive health, and beauty-from-within, among others.

Vice President, Product Development & Manufacturing: Cara Cesario, Ph.D.

SHY Thereapeutics logo

SHY Thereapeutics: developing small molecules therapeutics for the Ras Superfamily of Small GTPases.

Founder and CEO: Yaron Hadari, Ph.D.

New York R&D Center for Translational Medicine and Therapeutics, Inc. (NyTmT) is a biotechnology company that aims to develop innovative technologies and therapeutic products for musculoskeletal diseases such as tendinopathy and osteoarthritis.

CEO & President: David Fung, Ph.D.

Founder: Herb B. Sun, Ph.D.



Graduated Clients:



Advancing novel therapeutics for major unmet medical needs, particularly high-mortality cancers. Sapience Therapeutics’ lead candidate, ST-36, is a peptide-based drug that works as an inhibitor of activating transcription factor 5 (ATF5), which appears relevant to a number of different types of malignancies. ST-36 is designed to promote tumor cell death of glioblastoma multiforme (GBM), the most severe and deadly form of brain cancer.

Founder, President, and CEO: Barry Kappel, Ph.D., M.B.A.

Affina Biotechnologies

Affina Biotechnologies: Developing a first-in class treatment for late stage ovarian cancer using small hyper-interaction modulators (SHIMs) designed to repair function of mutant p53.

President and CSO: Alexander Vinitsky, Ph.D

MediSprout logo

MediSprout: Telemedicine platform to connect patients to their own doctors using a clinical HIPAA-compliant video communication solution.

Founder and CEO: Samant Virk, M.D.

Philips logo

Collaborative computational genomics research activities between Philips Healthcare, NYMC scientists and Westchester Medical Center. 

MKM Ventures

MKM Ventures: Developing cold electrical plasma systems and therapeutics to treat and remove onychomychosis (toenail fungus). Providing targeted destruction of pathogens and abnormal tissue externally avoids damage to surrounding healthy tissue and internal organs.

Co-Founder and CEO: Marc Zemel, S.M., M.B.A.

Retia Medical logo

Retia Medical was developed a cardiac output monitor which improves patient care by providing members of the critical care team with a more accurate, easy-to-use, and affordable hemodynamic monitor that supports confident, data-based decisions.

Co-Founder and CEO: Marc Zemel, S.M., M.B.A.

Digi Touch Logo

Digitouch Health, a digital health company that is developing technology that will empower anyone to measure their blood pressure with clinical accuracy by pressing a button on a smartphone or other mobile device. This technology will dramatically increase the ease and frequency of hypertension monitoring, leading to greater awareness and control of cardiovascular disease.

Founder and CEO: Marc Zemel, S.M., M.B.A.

MOE Medical Devices, LLC

MOE Medical Devices is developing cold electrical plasma systems and therapeutics to treat and remove toenail fungus.

Co-Founder and CEO: Marc Zemel, S.M., M.B.A.

SweetDefeat logo

Developed Sweet Defeat, a mint-flavored lozenge that is clinically proven to reduce consumption of and desire for high-sugar foods. The lozenge contains five high-quality, plant-based ingredients, and dissolves on your tongue to help stop sugar cravings within seconds. Sweet Defeat is an effective, safe, and convenient remedy that helps break the sugar-craving cycle so people can make better, healthier food choices without the risks or hassles of traditional supplements, diet pills, or behavior modification programs.

Chief Scientific Officer: Cara Cesario, Ph.D.